Q-omics provides the consensus-scored WDR33 profile across patient tissues and cancer cell-line models. WDR33 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, WDR33 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, WDR33 protein abundance shows 31,600 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where WDR33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WDR33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WDR33 survival associations across molecular data types. WDR33 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WDR33 RNA expression–survival associations across cancer types. High WDR33 expression shows unfavorable associations in KIRP, ACC and LIHC, but favorable associations in KIRC, THYM and CHOL. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for WDR33 RNA expression.
This table summarizes WDR33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for WDR33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WDR33 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LIHC, STAD and CHOL. The HNSC box plot shows higher WDR33 RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with WDR33 in patient tissues and cancer cell lines. In patient samples, WDR33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, WDR33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
